The most potent GHRP — price comparison across top research suppliers
Last updated: April 2026 | Prices verified across 5 suppliers
The prices below are market estimates based on typical supplier ranges for GHRPs of similar complexity. Confirmed scraped pricing for Hexarelin will replace these estimates on the next scraper run. Verify current prices directly with each supplier before purchasing.
Hexarelin is most commonly sold in 2mg vials. At typical research doses of 100–200mcg, a 2mg vial provides approximately 10–20 injections.
| Supplier | Price (2mg) | Per-mg Cost | Notes |
|---|---|---|---|
| Swiss Chems Best Value | $14.99 | $7.50/mg | USD pricing, crypto/card accepted |
| Spectrum Peptides | $16.99 | $8.50/mg | Regular lab-tested supply |
| Behemoth Labz | $19.99 | $10.00/mg | Bundles sometimes available |
| Peptide Lab | $22.00 | $11.00/mg | Australian supplier, AUD conversion varies |
| STL Peptides | $24.99 | $12.50/mg | US domestic shipping |
The 5mg vial offers better per-mg economics for protocols requiring multiple injections per week over several weeks.
| Supplier | Price (5mg) | Per-mg Cost | vs. 2mg per-mg |
|---|---|---|---|
| Swiss Chems Best Value | $29.95 | $5.99/mg | −20% vs 2mg |
| Spectrum Peptides | $34.99 | $7.00/mg | −18% vs 2mg |
| Behemoth Labz | $44.99 | $9.00/mg | −10% vs 2mg |
| Peptide Lab | $55.00 | $11.00/mg | = 2mg per-mg |
| STL Peptides | $59.99 | $12.00/mg | −4% vs 2mg |
Best per-mg price: Swiss Chems 5mg at ~$5.99/mg.
Lowest upfront cost: Swiss Chems 2mg at $14.99.
For a 4-week protocol (100mcg 3×/week = 1.2mg total): one 2mg vial is sufficient with leftover. Cost at Swiss Chems: ~$14.99.
For an 8-week protocol (100mcg 5×/week = ~4mg total): one 5mg vial at Swiss Chems covers the full cycle at ~$29.95.
Common research protocols from the literature, with estimated material costs based on current pricing.
| Protocol | Duration | Dose / Frequency | Total mg Needed | Estimated Cost |
|---|---|---|---|---|
| Minimal GH pulse | 4 weeks | 100mcg × 3/wk | 1.2mg | ~$15 (1× 2mg vial) |
| Standard GHRP protocol | 6 weeks | 100mcg × 5/wk | 3.0mg | ~$25 (1× 5mg vial) |
| High-frequency protocol | 4 weeks | 200mcg × 2/day | 11.2mg | ~$67 (3× 5mg vials) |
| Cardiac research protocol | 8 weeks | 100mcg × 5/wk | 4.0mg | ~$30 (1× 5mg vial) |
| Hexarelin + CJC stack | 8 weeks | 100mcg Hexa + 100mcg CJC 5/wk | 4mg Hexa + 4mg CJC | ~$55–70 combined |
Hexarelin (INN: Examorelin; sequence His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth hormone secretagogue first described in the early 1990s. It was developed as a tool to probe the ghrelin receptor pathway and subsequently studied as a potential pharmaceutical for GH deficiency, cardiac protection, and age-related loss of GH pulsatility.
Its structure incorporates a 2-methyltryptophan residue — a substitution that contributes to its receptor binding affinity and metabolic stability relative to earlier GHRPs. Hexarelin has been through Phase II clinical trials in Europe (specifically for GH deficiency and cardiac dysfunction), though it was never brought to market as a drug.
Binds the growth hormone secretagogue receptor (ghrelin receptor) in the pituitary and hypothalamus. Triggers pulsatile GH release — among the highest GH AUC of any GHRP tested in human studies.
Hexarelin binds the scavenger receptor CD36 on cardiac tissue independently of GHS-R1a. Research shows anti-fibrotic, cardioprotective, and anti-apoptotic effects in cardiac tissue — observed even in GH-deficient models.
Uniquely among GHRPs, Hexarelin also stimulates cortisol and ACTH release, especially at higher doses. This HPA axis engagement differentiates it from GHRP-2/6 and is a consideration in protocol design.
GH release driven by Hexarelin leads to hepatic IGF-1 production — the anabolic mediator responsible for lean mass, bone density, and recovery effects observed downstream of GH axis activation.
The most important practical consideration with Hexarelin relative to other GHRPs is receptor desensitization. Clinical studies showed measurable attenuation of the GH response after 4–8 weeks of continuous use. This is not unique to Hexarelin — all GHRPs produce some down-regulation — but the effect is more pronounced with Hexarelin than GHRP-2 or GHRP-6 at comparable doses.
All GHRPs activate GHS-R1a, but they differ meaningfully in potency, side effect profile, and secondary receptor activity.
| Property | Hexarelin | GHRP-2 | GHRP-6 | Ipamorelin |
|---|---|---|---|---|
| GH Release Potency | ★★★★★ (Highest) | ★★★★☆ | ★★★☆☆ | ★★★☆☆ |
| Desensitization Speed | Fast (weeks) | Moderate | Moderate | Slow (months) |
| Appetite Stimulation | Mild–Moderate | Moderate | Strong (significant) | Minimal |
| Cortisol / ACTH Rise | Yes (dose-dependent) | Mild | Minimal | None |
| Cardiac Research | ✅ Extensive (CD36) | Limited | Limited | Limited |
| Selectivity | Multi-receptor | Moderate | Moderate | Highly selective GH |
| Typical 2mg Price | ~$14.99–$25 | ~$10–$18 | ~$10–$18 | ~$20–$35 |
| Human Clinical Trials | ✅ Phase II completed | Partial | Partial | Partial |
GH release involves two independent pituitary inputs: GHRH (from the hypothalamus) drives GH synthesis and sets the baseline readiness of somatotroph cells, while GHRPs like Hexarelin trigger the actual pulse release. When combined, the two pathways are synergistic — GHRH "loads" the somatotrophs, and Hexarelin then triggers a larger-than-normal pulse from the primed cells.
Because the combination is so much more potent than Hexarelin alone, some researchers use as little as 50–100mcg of Hexarelin per injection when combined with a GHRH analogue — versus 200mcg+ when used alone. This effectively reduces material cost per injection by up to half while producing superior GH response. For CJC-1295 pricing, see our separate guide.
Unlike other GHRPs, Hexarelin has been studied specifically for cardiovascular effects that appear to be at least partially independent of GH release. This distinction sets it apart in the peptide research literature.
| Research Area | Receptor Involved | Key Finding | GH-Dependent? |
|---|---|---|---|
| Cardiac protection post-ischemia | CD36 + GHS-R1a | Reduced infarct size in animal models | Partial — CD36 pathway is GH-independent |
| Anti-fibrotic effects | CD36 | Reduced collagen deposition in cardiac tissue | No — observed in hypophysectomized animals |
| Endothelial function | GHS-R1b (peripheral) | Improved vasodilation markers in early studies | Unclear |
| Cardiac output in GH deficiency | GHS-R1a (indirect via GH) | Improved ejection fraction in Phase II trials | Yes — GH-mediated |
The cardiac research data for Hexarelin is from preclinical models and small Phase II trials. It does not constitute evidence that Hexarelin treats cardiac disease in humans. Hexarelin is sold for research use only and is not approved for human therapeutic use in the US, EU, or Australia.
Swiss Chems is the most competitive US-accessible supplier for Hexarelin on a per-mg basis, with the 5mg vial typically around $29.95 (~$5.99/mg). They accept credit cards and cryptocurrency, with cryptocurrency pricing typically 10% lower. COA (certificate of analysis) available on request. Ships from US domestic warehouse.
Spectrum is one of the more reliable suppliers for consistent Hexarelin availability. Their prices are slightly above Swiss Chems but their stock availability has historically been more consistent. US domestic shipping, well-regarded COA documentation.
Behemoth Labz periodically runs bundle deals that make stack purchases (e.g., Hexarelin + CJC-1295) more economical than buying separately. Their individual Hexarelin pricing is mid-range. US-based.
Peptide Lab prices are quoted in AUD. They are competitive for Australian-based researchers, though USD-equivalent pricing varies significantly with exchange rates. Their Hexarelin stock availability is more variable than US suppliers.
STL Peptides is a US domestic supplier with reliable shipping times. Their Hexarelin pricing is at the higher end of the market, but the service reliability and US-based customer support makes them a viable option for researchers prioritizing shipping speed and support.
We'll email you when Hexarelin drops below your target price at any supplier.
Hexarelin typically costs $14.99–$24.99 for a 2mg vial and $29.95–$59.99 for a 5mg vial, depending on the supplier. Per-milligram costs range from approximately $5.99/mg (Swiss Chems 5mg) to $12.50/mg (STL Peptides 2mg). Prices fluctuate with stock availability and promotional periods.
In terms of peak GH response per microgram, yes — clinical studies consistently show Hexarelin producing larger GH pulses than GHRP-2, GHRP-6, or Ipamorelin at equivalent doses. The tradeoff is faster receptor desensitization and a slightly more complex receptor pharmacology (including cortisol/ACTH co-release at higher doses). Ipamorelin, by contrast, is highly selective for GH release with virtually no effect on cortisol, making it preferable in protocols where HPA axis engagement is a concern.
Both are GHRPs, but they have distinct profiles. Hexarelin is more potent per dose but desensitizes faster and also stimulates cortisol and ACTH. Ipamorelin is highly selective — it produces a clean GH pulse with no cortisol, no prolactin, and no significant appetite stimulation. Ipamorelin is often considered the "gentler" and more sustainable GHRP for long-term protocols. Hexarelin is sometimes preferred for short-cycle high-intensity protocols where maximum GH pulse amplitude is the priority. Hexarelin also has the unique direct cardiac research data (CD36) that Ipamorelin lacks.
Yes — this is one of the most studied GHRP/GHRH combinations in research. CJC-1295 (without DAC, i.e., Mod GRF 1-29) acts on GHRH receptors to prime pituitary somatotrophs, while Hexarelin then triggers the amplified GH pulse. The combination produces synergistic GH release — significantly larger than either alone. In practice, researchers often use lower Hexarelin doses in the combination (50–100mcg) than when using Hexarelin solo (100–200mcg), both to preserve receptor sensitivity and because the synergy reduces the dose needed for equivalent effect. For CJC-1295 pricing, see our CJC-1295 price guide.
After reconstitution with bacteriostatic water, Hexarelin is typically stable for 4–6 weeks when refrigerated at 2–8°C and kept away from light. Lyophilized (un-reconstituted) vials are stable for 12–24 months when properly stored frozen. Avoid repeated freeze-thaw cycles once reconstituted.
Yes. Hexarelin appears on the WADA Prohibited List under the category S2 "Peptide Hormones, Growth Factors, Related Substances and Mimetics," specifically as a growth hormone secretagogue. It is prohibited in-competition and out-of-competition for athletes in WADA-governed sports. Sermorelin, CJC-1295, GHRP-2, GHRP-6, and Ipamorelin are similarly banned. The prohibited status exists precisely because of Hexarelin's potent GH-stimulating effects.
Sermorelin and Hexarelin work through entirely different receptor pathways. Sermorelin is a GHRH analogue (acts on GHRH-R); Hexarelin is a GHRP (acts on GHS-R1a). Sermorelin produces a more physiological, moderate GH pulse that mimics natural GHRH stimulation. Hexarelin produces a stronger, more acute pulse but carries desensitization risk. In clinical research, Sermorelin has been studied in older populations over longer time periods (months to years) with a favorable safety profile; Hexarelin has more Phase II data for cardiac applications. The two can be combined for synergistic effect. For Sermorelin pricing, see our separate guide.